PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter

被引:14
作者
Hegedues, Csilla [1 ,2 ]
Truta-Feles, Krisztina [1 ,2 ]
Antalffy, Geza [1 ,2 ]
Brozik, Anna [3 ]
Kasza, Ildiko [1 ,2 ]
Nemet, Katalin [1 ,2 ]
Orban, Tamas I. [1 ,2 ]
Oezvegy-Laczka, Csilla [1 ,2 ]
Varadi, Andras [3 ]
Sarkadi, Balazs [1 ,2 ,4 ]
机构
[1] Semmelweis Univ, Hungarian Acad Sci, Membrane Res Grp, Dept Biophys, H-1113 Budapest, Hungary
[2] Natl Blood Ctr, Budapest, Hungary
[3] Hungarian Acad Sci, Inst Enzymol, Res Ctr Nat Sci, Budapest, Hungary
[4] Hungarian Acad Sci, Inst Mol Pharmacol, Res Ctr Nat Sci, Budapest, Hungary
关键词
ABCG2; PI3-kinase/Akt/mTOR signaling; LY294002; Wortmannin; Rapamycin; SIDE-POPULATION PHENOTYPE; KINASE INHIBITORS; DRUG TRANSPORT; CYCLOSPORINE-A; CELL-SURFACE; RESISTANCE; EXPRESSION; AKT; BCRP/ABCG2; PATHWAY;
D O I
10.1016/j.bbrc.2012.03.090
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ATP-binding cassette (ABC) transporter ABCG2 plays an important role in tissue detoxification and confers multidrug resistance to cancer cells. Identification of expressional and functional cellular regulators of this multidrug transporter is therefore intensively pursued. The PI3-kinase/Akt signaling axis has been implicated as a key element in regulating various cellular functions, including the expression and plasma membrane localization of ABCG2. Here we demonstrate that besides inhibiting their respective target kinases, the pharmacological PI3-kinase inhibitor LY294002 and the downstream mTOR kinase inhibitor rapamycin also directly inhibit ABCG2 function. In contrast, wortmannin, another commonly used pharmacological inhibitor of PI3-kinase does not interact with the transporter. We suggest that direct functional modulation of ABCG2 should be taken into consideration when pharmacological agents are applied to dissect the specific role of PI3-kinase/Akt/mTOR signaling in cellular functions. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:869 / 874
页数:6
相关论文
共 28 条
[1]   The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1 [J].
Abdul-Ghani, R ;
Serra, V ;
Györffy, B ;
Jürchott, K ;
Solf, A ;
Dietel, M ;
Schäfer, R .
ONCOGENE, 2006, 25 (12) :1743-1752
[2]   Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium [J].
Aust, S ;
Obrist, P ;
Jaeger, W ;
Klimpfinger, M ;
Tucek, G ;
Wrba, F ;
Penner, E ;
Thalhammer, T .
LABORATORY INVESTIGATION, 2004, 84 (08) :1024-1036
[3]   PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells [J].
Bleau, Anne-Marie ;
Hambardzumyan, Dolores ;
Ozawa, Tatsuya ;
Fomchenko, Elena I. ;
Huse, Jason T. ;
Brennan, Cameron W. ;
Holland, Eric C. .
CELL STEM CELL, 2009, 4 (03) :226-235
[4]   Ten years of protein kinase B signalling: a hard Akt to follow [J].
Brazil, DP ;
Hemmings, BA .
TRENDS IN BIOCHEMICAL SCIENCES, 2001, 26 (11) :657-664
[5]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105
[6]   Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib) [J].
Elkind, NB ;
Szentpétery, Z ;
Apáti, A ;
Özvegy-Laczka, C ;
Várady, G ;
Ujhelly, O ;
Szabó, K ;
Homolya, L ;
Váradi, A ;
Buday, L ;
Kéri, G ;
Német, K ;
Sarkadi, B .
CANCER RESEARCH, 2005, 65 (05) :1770-1777
[7]   Current development of mTOR inhibitors as anticancer agents [J].
Faivre, Sandrine ;
Kroemer, Guido ;
Raymond, Eric .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) :671-688
[8]   Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells [J].
Goler-Baron, Vicky ;
Sladkevich, Irina ;
Assaraf, Yehuda G. .
BIOCHEMICAL PHARMACOLOGY, 2012, 83 (10) :1340-1348
[9]   Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan [J].
Gupta, Anshul ;
Dai, Yang ;
Vethanayagam, R. Robert ;
Hebert, Mary F. ;
Thummel, Kenneth E. ;
Unadkat, Jashvant D. ;
Ross, Douglas D. ;
Mao, Qingcheng .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (03) :374-383
[10]   Ins and outs of the ABCG2 multidrug transporter: An update on in vitro functional assays [J].
Hegedus, Csilla ;
Szakacs, Gergely ;
Homolya, Laszlo ;
Orban, Tamas I. ;
Telbisz, Agnes ;
Jani, Marton ;
Sarkadi, Balazs .
ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (01) :47-56